Literature DB >> 8783769

Generalized lipodystrophy, congenital and acquired (lipoatrophy).

M Seip1, O Trygstad.   

Abstract

This review is based on longitudinal studies on our seven patients with congenital generalized lipodystrophy, our patient with acquired generalized lipodystrophy, and published papers on these subjects. An inability to store energy in adipose tissue is of pathogenetic importance. In congenital lipodystrophy, insulin resistance is present from birth, resulting in hyperinsulinaemia, dyslipidaemia. and insulin-resistant diabetes with an anabolic syndrome worsened by a voracious appetite. Clinically, we observed increased height velocity in pre-school age children, and organomegaly with hypertrophic cardiomyopathy, which seems to be lethal in early adulthood: three of our patients died at the ages of 24, 32 and 37 years. The oldest alive, 39 years, suffers from stenocardia. Regarding treatment, it is most important to reduce energy consumption. The congenital form is recessively inherited. The aetiology may be related to insulin receptor or postreceptor mechanisms. Acquired generalized lipodystrophy seems to be an autoimmune disorder with secondary destruction of the adipose organ: the anabolic syndrome with insulin-resistant diabetes is secondary. Our patient died when 24 years old from pneumonia.

Entities:  

Mesh:

Year:  1996        PMID: 8783769     DOI: 10.1111/j.1651-2227.1996.tb14262.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  65 in total

1.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice.

Authors:  O Gavrilova; B Marcus-Samuels; D Graham; J K Kim; G I Shulman; A L Castle; C Vinson; M Eckhaus; M L Reitman
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 2.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 3.  Obesidomics: contribution of adipose tissue secretome analysis to obesity research.

Authors:  Maria Pardo; Arturo Roca-Rivada; Luisa Maria Seoane; Felipe F Casanueva
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

4.  Repositioning HIV protease inhibitors as cancer therapeutics.

Authors:  Wendy B Bernstein; Phillip A Dennis
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

5.  Molecular characterization, chromosomal localization and association analysis with back-fat thickness of porcine LPIN2 and LPIN3.

Authors:  Xiaoping He; Xuewen Xu; Bang Liu
Journal:  Mol Biol Rep       Date:  2008-11-07       Impact factor: 2.316

Review 6.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

7.  Investigation of Lpin1 as a candidate gene for fat deposition in pigs.

Authors:  X P He; X W Xu; S H Zhao; B Fan; M Yu; M J Zhu; C C Li; Z Z Peng; B Liu
Journal:  Mol Biol Rep       Date:  2008-06-26       Impact factor: 2.316

Review 8.  Genetics of insulin resistance.

Authors:  Maria M Mercado; John C McLenithan; Kristi D Silver; Alan R Shuldiner
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

9.  Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice.

Authors:  Weiqin Chen; Hongyi Zhou; Pradip Saha; Luge Li; Lawrence Chan
Journal:  Endocrinology       Date:  2014-08-05       Impact factor: 4.736

10.  Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.

Authors:  Víctor A Cortés; David E Curtis; Suja Sukumaran; Xinli Shao; Vinay Parameswara; Shirya Rashid; Amy R Smith; Jimin Ren; Victoria Esser; Robert E Hammer; Anil K Agarwal; Jay D Horton; Abhimanyu Garg
Journal:  Cell Metab       Date:  2009-02       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.